Verrica Pharmaceuticals (NASDAQ:VRCA) Earns “Hold” Rating from Needham & Company LLC

Needham & Company LLC reiterated their hold rating on shares of Verrica Pharmaceuticals (NASDAQ:VRCA) in a report published on Wednesday morning,Benzinga reports.

Separately, HC Wainwright reissued a “neutral” rating on shares of Verrica Pharmaceuticals in a research note on Tuesday. Four research analysts have rated the stock with a hold rating and one has given a buy rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average price target of $9.50.

Verrica Pharmaceuticals Trading Up 10.0 %

Verrica Pharmaceuticals stock opened at $0.48 on Wednesday. Verrica Pharmaceuticals has a 52 week low of $0.38 and a 52 week high of $11.41. The stock has a market cap of $44.42 million, a price-to-earnings ratio of -0.26 and a beta of 1.68. The company’s 50-day moving average price is $0.60 and its two-hundred day moving average price is $0.86.

Verrica Pharmaceuticals (NASDAQ:VRCA) last posted its quarterly earnings data on Tuesday, March 11th. The company reported ($0.24) EPS for the quarter, beating analysts’ consensus estimates of ($0.25) by $0.01. Verrica Pharmaceuticals had a negative net margin of 625.06% and a negative return on equity of 591.84%. The business had revenue of $0.34 million for the quarter, compared to analyst estimates of $1.30 million. Research analysts expect that Verrica Pharmaceuticals will post -1.46 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Verrica Pharmaceuticals

A number of institutional investors have recently bought and sold shares of the stock. Caligan Partners LP acquired a new position in shares of Verrica Pharmaceuticals in the fourth quarter worth about $5,201,000. Boothbay Fund Management LLC purchased a new stake in shares of Verrica Pharmaceuticals in the 4th quarter valued at approximately $1,811,000. State Street Corp boosted its stake in Verrica Pharmaceuticals by 13.5% in the 3rd quarter. State Street Corp now owns 512,821 shares of the company’s stock worth $744,000 after purchasing an additional 61,041 shares during the period. Geode Capital Management LLC grew its position in Verrica Pharmaceuticals by 4.8% during the 4th quarter. Geode Capital Management LLC now owns 477,269 shares of the company’s stock worth $334,000 after purchasing an additional 21,789 shares in the last quarter. Finally, Sovran Advisors LLC acquired a new stake in Verrica Pharmaceuticals during the 4th quarter valued at $267,000. Hedge funds and other institutional investors own 42.45% of the company’s stock.

Verrica Pharmaceuticals Company Profile

Verrica Pharmaceuticals Inc, a clinical-stage dermatology therapeutics company, develops medications for the treatment of skin diseases in the United States. Its product pipeline comprises YCANTH (VP-102), which is in phase III clinical trial for the treatment of common warts; and has completed phase II clinical trial for the treatment of external genital warts.